Podcasts

Steering Committee members Professor Ed Vital, who is a Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust, UK, is joined by Professor Richard Furie, who is Chief of the Division of Rheumatology at the Department of Medicine, Northwell Health, New York, and Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell, and Professor Liz Lightstone, from the Imperial College Healthcare NHS Trust Renal and Transplant Centre, Hammersmith, London, on the latest Lupus Forum podcast.

Together, they discuss defining ANA-associated arthritis and proposing new basket trial groupings, as well as evaluating the achievement of EULAR/ERA-EDTA treatment targets in lupus nephritis and the need for therapy adjustments.

Steering Committee members Professor Chris Edwards from the University Hospital Southampton NHS Foundation Trust is joined by Professor Victoria Werth, from the Philadelphia Veterans Administration Hospital, Pennsylvania, USA on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with SLE, as well as CD19-CAR T-cell therapy inducing B cell deep tissue depletion!

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Doctor Antony Psarras, an NIHR Academic Clinical Lecturer in Rheumatology at the University of Oxford and at the Kennedy Institute of Rheumatology.

Together, they discuss the use of CD163 as a marker for diagnosis and flare in lupus nephritis. They also discuss the impact of discontinuing immunosuppression on the disease, in particular looking at novel research surrounding the predictors of flares, time to withdrawal and long-term outcomes.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss the efficacy and safety of upadacitinib and elsubrutinib combination and monotherapy, as well as the association of LLDAS with improved outcomes in SLE.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss predictors of belimumab renal response in lupus nephritis, and the efficacy and safety of telitacicept in SLE with haematological involvement.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Brad Rovin, Professor of Nephrology and Medical Director of the Ohio State University Clinical Research Management Institute. Together, they discuss the use of belimumab to reduce prednisone doses and the development of the SLESIS-R score for determining the risk of severe infection in SLE.